{{Multiple issues|
{{globalize|date=July 2016}}
{{update|date=July 2016}}
}}

{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 407801391
| IUPAC_name = 4-methyl-''N''-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
| image =Minaprine.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|minaprine}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life = 2-2.5 hours
| excretion =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 25905-77-5
| ATC_prefix = N06
| ATC_suffix = AX07
| PubChem = 4199
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4054
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 00U7GX0NLM
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05039
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 278819
<!--Chemical data-->
| C=17 | H=22 | N=4 | O=1
| molecular_weight = 298.383 g/mol
| smiles = CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3
}}

'''Minaprine''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) (brand names '''Brantur''', '''Cantor''') is a [[monoamine oxidase inhibitor]] [[antidepressant]] drug that was used in [[France]] for the treatment of [[major depression|depression]] until it was [[withdrawn drug|withdrawn]] from the market in 1996 because it caused [[convulsion]]s.<ref name=Fung-2001>{{cite journal|last=Fung|first=M.|author2=Thornton, A. |author3=Mybeck, K. |author4=Wu, J. H.-h. |author5=Hornbuckle, K. |author6= Muniz, E. |title=Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999|journal=Therapeutic Innovation & Regulatory Science|date=1 January 2001|volume=35|issue=1|pages=293–317|doi=10.1177/009286150103500134}}</ref>

A study found that it acts as a [[reversible inhibitor of monoamine oxidase A|reversible inhibitor of MAO-A]] (RIMA) in rats.<ref>{{ cite journal |vauthors=Kan JP, Mouget-Goniot C, Worms P, Biziere K | title = Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat | journal = [[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] | year = 1986 | volume = 35 | issue = 6 | pages = 973–978 | pmid = 3954800 | doi=10.1016/0006-2952(86)90085-7}}</ref> In a study it has also been found to weakly [[enzyme inhibitor|inhibit]] [[acetylcholinesterase]] in rat brain (striatum) homogenates.<ref>{{ cite journal |vauthors=Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG | title = Aminopyridazines as acetylcholinesterase inhibitors | journal = Journal of Medicinal Chemistry | year = 1999 | volume = 42 | issue = 4 | pages = 730–741 | pmid = 10052979 | doi=10.1021/jm981101z}}</ref>

==References==
{{reflist|30em}}

{{Antidepressants}}
{{Acetylcholine metabolism and transport modulators}}
{{Monoamine metabolism modulators}}

[[Category:Acetylcholinesterase inhibitors]]
[[Category:Antidepressants]]
[[Category:Aromatic amines]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Morpholines]]
[[Category:Pyridazines]]


{{Nervous-system-drug-stub}}